Cargando…

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

BACKGROUND: The immune profile against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically diversified due to a complex combination of exposure to vaccines and infection by various lineages/variants, likely generating a heterogeneity in protective immunity in a given popula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyamoto, Sho, Arashiro, Takeshi, Adachi, Yu, Moriyama, Saya, Kinoshita, Hitomi, Kanno, Takayuki, Saito, Shinji, Katano, Harutaka, Iida, Shun, Ainai, Akira, Kotaki, Ryutaro, Yamada, Souichi, Kuroda, Yudai, Yamamoto, Tsukasa, Ishijima, Keita, Park, Eun-Sil, Inoue, Yusuke, Kaku, Yoshihiro, Tobiume, Minoru, Iwata-Yoshikawa, Naoko, Shiwa-Sudo, Nozomi, Tokunaga, Kenzo, Ozono, Seiya, Hemmi, Takuya, Ueno, Akira, Kishida, Noriko, Watanabe, Shinji, Nojima, Kiyoko, Seki, Yohei, Mizukami, Takuo, Hasegawa, Hideki, Ebihara, Hideki, Maeda, Ken, Fukushi, Shuetsu, Takahashi, Yoshimasa, Suzuki, Tadaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Clinical and Translational Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894731/ https://www.ncbi.nlm.nih.gov/pubmed/35261995 http://dx.doi.org/10.1016/j.medj.2022.02.006

Ejemplares similares

Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization
por: Miyamoto, Sho, et al.
Publicado: (2023)

Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval
por: Miyamoto, Sho, et al.
Publicado: (2023)

Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology
por: Hemmi, Takuya, et al.
Publicado: (2022)

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
por: Ohashi, Hirofumi, et al.
Publicado: (2022)

Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters
por: Shiwa-Sudo, Nozomi, et al.
Publicado: (2023)

Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses
por: Kotani, Osamu, et al.
Publicado: (2021)

A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection
por: Iwata-Yoshikawa, Naoko, et al.
Publicado: (2022)

Characterization of Quasispecies of Pandemic 2009 Influenza A Virus (A/H1N1/2009) by De Novo Sequencing Using a Next-Generation DNA Sequencer
por: Kuroda, Makoto, et al.
Publicado: (2010)

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022)

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
por: Moriyama, Saya, et al.
Publicado: (2021)

Assessment of SARS-CoV-2 infectivity of upper respiratory specimens from COVID-19 patients by virus isolation using VeroE6/TMPRSS2 cells
por: Yamada, Souichi, et al.
Publicado: (2021)

High expression of JC polyomavirus-encoded microRNAs in progressive multifocal leukoencephalopathy tissues and its repressive role in virus replication
por: Takahashi, Kenta, et al.
Publicado: (2020)

Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant–Infected Vaccinees
por: Takahashi, Kenichiro, et al.
Publicado: (2022)

Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
por: Sonoyama, Takuhiro, et al.
Publicado: (2023)

Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection
por: Kawaguchi, Akira, et al.
Publicado: (2017)

An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody
por: Sano, Kaori, et al.
Publicado: (2021)

cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue
por: Takaki, Hiromi, et al.
Publicado: (2017)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Roles of GP33, a guinea pig cytomegalovirus-encoded G protein-coupled receptor homolog, in cellular signaling, viral growth and inflammation in vitro and in vivo
por: Takeda, Miei, et al.
Publicado: (2018)

IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody
por: Saito, Shinji, et al.
Publicado: (2019)

Pathology of Kaposi’s Sarcoma-Associated Herpesvirus Infection
por: Fukumoto, Hitomi, et al.
Publicado: (2011)

Frequent detection of Merkel cell polyomavirus DNA in sera of HIV-1-positive patients
por: Fukumoto, Hitomi, et al.
Publicado: (2013)

Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults
por: Ainai, Akira, et al.
Publicado: (2013)

Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways
por: Iwata-Yoshikawa, Naoko, et al.
Publicado: (2022)

Dengue virus infection induces selective expansion of Vγ4 and Vγ6TCR γδ T cells in the small intestine and a cytokine storm driving vascular leakage in mice
por: Kurosu, Takeshi, et al.
Publicado: (2023)

Serological Assays Based on Recombinant Viral Proteins for the Diagnosis of Arenavirus Hemorrhagic Fevers
por: Fukushi, Shuetsu, et al.
Publicado: (2012)

Conserved sequences of BART and BHRF regions encoding viral microRNAs in Epstein-Barr virus-associated lymphoma
por: Sunagawa, Keishin, et al.
Publicado: (2017)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine
por: Kotaki, Ryutaro, et al.
Publicado: (2022)

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
por: Hasegawa, Hideki, et al.
Publicado: (2009)

Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets
por: Mine, Sohtaro, et al.
Publicado: (2017)

Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
por: Shimojima, Masayuki, et al.
Publicado: (2015)

Inability of rat DPP4 to allow MERS-CoV infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike protein
por: Fukuma, Aiko, et al.
Publicado: (2015)

Coronavirus hunted in human pneumocytes and alveolar macrophages: a case report
por: Kataoka, Michiyo, et al.
Publicado: (2022)

Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys
por: Hashimoto, Masayuki, et al.
Publicado: (2022)

Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes
por: Shibamura, Miho, et al.
Publicado: (2020)

Acute Respiratory Infection in Human Dipeptidyl Peptidase 4-Transgenic Mice Infected with Middle East Respiratory Syndrome Coronavirus
por: Iwata-Yoshikawa, Naoko, et al.
Publicado: (2019)

Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus
por: Tani, Hideki, et al.
Publicado: (2016)

Insights into Pathology and Pathogenesis of Coronavirus Disease 2019 from a Histopathological and Immunological Perspective
por: Iida, Shun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_laenoqj7sav7p0ofe9nhregshs